肝门部附近肝细胞癌的质子束治疗
Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis.
作者信息
Mizumoto Masashi, Tokuuye Koichi, Sugahara Shinji, Nakayama Hidetsugu, Fukumitsu Nobuyoshi, Ohara Kiyoshi, Abei Masato, Shoda Junichi, Tohno Eriko, Minami Manabu
机构信息
Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
出版信息
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):462-7. doi: 10.1016/j.ijrobp.2007.09.056. Epub 2008 Feb 19.
PURPOSE
To evaluate the efficacy and safety of proton beam therapy (PBT) for patients with hepatocellular carcinoma (HCC) located adjacent to the porta hepatis.
METHODS AND MATERIALS
Subjects of the study were 53 patients with HCC located within 2 cm of the main portal vein. All patients had tumor confined to the radiation field with no evidence of metastatic disease. All patients had hepatic function levels of a Child-Pugh score of 10 or less, Eastern Cooperative Oncology Group performance status of 2 or less, and no uncontrolled ascites. Patients underwent PBT of 72.6 GyE in 22 fractions from Sept 2001 to Dec 2004.
RESULTS
After 3 years, the actuarial survival rate was 45.1% and local control rate was 86.0%. Prognostic factors for survival included Child-Pugh score, number of tumors, and alpha-fetoprotein levels. No late treatment-related toxicity of Grade 2 or higher was observed.
CONCLUSIONS
The PBT delivering 72.6 GyE in 22 fractions appears to be effective and safe for HCC adjacent to the porta hepatis.
目的
评估质子束治疗（PBT）对肝门部附近肝细胞癌（HCC）患者的疗效和安全性。
方法和材料
本研究的对象为53例主要门静脉周围2厘米内的HCC患者。所有患者肿瘤局限于放射野内，无转移疾病证据。所有患者的肝功能水平为Child-Pugh评分10分或更低，东部肿瘤协作组体能状态评分为2分或更低，且无无法控制的腹水。2001年9月至2004年12月，患者接受了22次分割、总剂量72.6 GyE的PBT治疗。
结果
3年后，精算生存率为45.1%，局部控制率为86.0%。生存的预后因素包括Child-Pugh评分、肿瘤数量和甲胎蛋白水平。未观察到2级或更高等级的晚期治疗相关毒性。
结论
22次分割给予72.6 GyE的PBT对肝门部附近的HCC似乎有效且安全。
Zotero 插件